[CAS NO. 1203494-49-8] DASA-58

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1203494-49-8]

Catalog

HY-19330

Brand

MCE

CAS

1203494-49-8

DESCRIPTION [1203494-49-8]

Overview

MDL	MFCD29472280
Molecular Weight	453.53
Molecular Formula	C19H23N3O6S2
SMILES	NC1=CC=CC(S(=O)(N2CCN(S(=O)(C3=CC=C(OCCO4)C4=C3)=O)CCC2)=O)=C1

For research use only. We do not sell to patients.

12 Publications Citing Use of MCE

Summary

DASA-58 is a potential pyruvate kinase isozyme (PKM2) allosteric activator. DASA-58 can be used for the research of metabolism and kinds of cancer ^[1] .

In Vitro

DASA-58 (15 μM; 2 h) potentiates the antitumor effects of other metabolic stressors ^[1] .
DASA-58 (15 μM; 24 h, 72 h) enhances pyruvate kinase activity in breast cancer cells without a clear effect on proliferation ^[1] .
DASA-58 (30 μM, 60 μM; 0-72 h) enhances extracellular acidification and lactate levels in BCa cell lines and induce extracellular acidification levels in prostate cancer cell lines ^[1] .
DASA-58 (15 μM, 30 μM; 0-72 h) affects respiration levels in BCa cells without an indication of mitochondrial damage ^[1] .
DASA-58 (15 μM; 0-72 h) not rescues TXNIP levels in any combintion and mitochondrial inhibitors enhance PKM2 effects on activating AMPK signaling (T172 phosphorylation of AMPK) ^[1] .
DASA-58 (15 μM; 0-72 h) leads to depletion in TXNIP levels independent of AMPK and ER signaling, and not through enhanced proteasomal degradation but rather depleted upstream glycolytic intermediates ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	Five breast cancer cell lines (BCa cells) (MDA MB 231, MDA MB 468, HCC 1443, T47-D, MCF7, LnCap, PC3, and DU145)
Concentration:	15 μM
Incubation Time:	2 h
Result:	Could be exploited by other metabolic stressors.

Western Blot Analysis ^[1]

Cell Line:	BCa cells
Concentration:	15 μM
Incubation Time:	24 h, 72 h
Result:	Showed comparable PKM2 protein levels in five breast cancer cell lines, except HCC1443 cells and MDA MB 468 that showed the highest and lowest PKM2 protein levels, respectively. Not changed PKM2 levels in five breast cancer cell lines but seemingly reduced TXNIP levels in cells expressing detectable TXNIP levels.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 35 mg/mL ( 77.17 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2049 mL	11.0246 mL	22.0493 mL
5 mM	0.4410 mL	2.2049 mL	4.4099 mL
10 mM	0.2205 mL	1.1025 mL	2.2049 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Fadi Almouhanna, et al. Pharmacological activation of pyruvate kinase M2 reprograms glycolysis leading to TXNIP depletion and AMPK activation in breast cancer cells. Cancer Metab. 2021 Jan 22;9(1):5.